ArticleBMC cardiovascular disorders2026
Metabolic score for visceral fat profiles and incident cardiovascular disease in adults with CKM syndrome stages 0-3: a CHARLS longitudinal study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe Metabolic Score for Visceral Fat (METS-VF) is a novel index reflecting visceral adiposity and metabolic dysfunction, but its association with incident cardiovascular disease (CVD) in adults with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3 remains unclear. This study aimed to explore this association and quantify the mediating effect of estimated glucose disposal rate (eGDR).
methodsUtilizing data from the China Health and Retirement Longitudinal Study (CHARLS), we prospectively followed 3,815 adults with CKM syndrome stages 0-3 (baseline 2015) until 2020. The METS-VF profiles comprised baseline METS-VF, cumulative METS-VF, and change patterns identified by latent class growth modeling (LCGM). To investigate associations and underlying mechanisms, Cox proportional-hazards regression, weighted quantile sum (WQS) regression, and mediation analysis were employed. Sensitivity analyses (stratification by CKM syndrome stage and demographics, inverse probability weighting [IPW], Fine-Gray model) were used to support the robustness of the results.
resultsOver a mean 4.4-year follow-up, 18.7% of participants developed CVD. In the fully adjusted model, elevated METS-VF profiles were associated with an increased risk of CVD: baseline METS-VF in the fourth quartile (HR = 1.615, 95% confidence interval (CI): 1.243-2.097), cumulative METS-VF in the fourth quartile (HR = 1.824, 95% CI: 1.397-2.381), and stable high-level METS-VF (Class 3) (HR = 1.288, 95% CI: 1.033-1.610). All associations remained significant following false discovery rate (FDR) correction. Stratified analyses showed stronger associations between METS-VF profiles and incident CVD in late-stage (vs. early-stage) CKM syndrome, with the association more pronounced in males-females only had significant associations in the highest quartile. WQS regression identified Metabolic Score for Insulin Resistance (METS-IR) as the primary contributing factor, with weights of 0.397 in 2011 and 0.375 in 2015. Mediation analysis indicated that eGDR mediated 65.38% of the baseline and 56.72% of the cumulative effects (both P < 0.001). Supplementary mediation analysis using body mass index (BMI)-based METS-VF
conclusionsMETS-VF profiles are independently associated with incident CVD in CKM syndrome stages 0-3, more strongly in late stages. eGDR significantly mediates this relationship, supporting the "obesity-metabolism-vascular" axis. METS-VF may aid CVD risk stratification in CKM syndrome populations, and targeting insulin sensitivity may mitigate CVD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.